Ebola virus glycoprotein mucin-like domain (EBOV GP-MLD)

The Ebola virus glycoprotein (GP) is the sole protein expressed on the virion surface, facilitating attachment, membrane fusion, and entry into host cells (UniProt P87666). The mucin-like domain (MLD) is a highly glycosylated region of the GP1 subunit that projects outward, forming a "glycan shield" that protects conserved epitopes from immune detection (PubMed: 25471885). While the MLD is proteolytically removed by host cathepsins within the endosome to expose the receptor-binding site for Niemann-Pick C1 (NPC1), it remains a primary target for the humoral immune response during the extracellular phase of the viral life cycle (PubMed: 21994305). Antibodies targeting MLD epitopes, such as the 13C6 monoclonal antibody found in the ZMapp cocktail, provide protection by neutralizing the virus or recruiting immune effector cells to clear infected cells (PubMed: 25131920). However, the MLD's high degree of sequence variability and dense O-linked and N-linked glycosylation pose significant challenges for the development of broad-spectrum vaccines and therapeutics (PubMed: 26416914).

Other names

GP1 mucin-like domainEbola virus GP MLDMucin-like domain of GP1EBOV GP-MLD epitope

Antibodies targeting the MLD epitope primarily function by blocking viral attachment to host cell surface lectins (such as DC-SIGN or L-SIGN) or by mediating immune effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) (PubMed: 25131920, 26416914).